The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered ...

CapsoVision has filed to go public, with plans to raise up to $30 million to support the development of its swallowable ...

Biotech bank balances were again in focus Monday morning, with Tango Therapeutics cutting preclinical work to stretch its ...

Lexeo Therapeutics laid off 15% of its staff last month as part of a wider plan to siphon $20 million from its wider pipeline ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

Dynavax’s battle with activist investor Deep Track Capital over the biopharma’s direction has heated up again as the ...

The FDA has appointed its first chief artificial intelligence officer, with an eye on supporting the agency’s internal IT ...

Following the FDA’s clearance earlier this year of its large-bore catheter for removing oxygen-blocking blood clots, ...

Qilu Pharmaceutical is paying 280 million Chinese yuan ($38 million) for a licensing and collaboration deal with fellow China ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its ...

The phase 2b trial compared four doses of temtokibart to placebo in 262 adults with moderate to severe atopic dermatitis, the ...